0.90

2.80% 0.0245

Scynexis Inc (SCYX)

Overview News Price History Option Chain Financials Why SCYX Down? Discussions Forecast Stock Split

Scynexis Inc stock is traded at $0.90, with a volume of 120.10K. It is up +2.80% in the last 24 hours and up +14.37% over the past month. SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Previous Close:

$0.8755

Open:

$0.89

24h Volume:

120.10K

Relative Volume:

0.29

Market Cap:

$40.20M

Revenue:

$20.60M

Net Income/Loss:

$-8.61M

P/E Ratio:

-6.517

EPS:

-0.1381

Net Cash Flow:

$-5.28M

1W Performance:

-2.23%

1M Performance:

+14.37%

6M Performance:

-17.43%

1Y Performance:

-13.46%

1-Day Range:

$0.865

$0.9038

1-Week Range:

$0.865

$0.95

52-Week Range:

$0.565

$1.31

Scynexis Inc Stock (SCYX) Company Profile

Name

Scynexis Inc

Sector

Healthcare (1113)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

201-884-5485

Address

1 EVERTRUST PLAZA, JERSEY CITY, NJ

Employee

Twitter

@scynexis

Next Earnings Date

2024-11-11

Latest SEC Filings

SCYX's Discussions on Twitter

Compare SCYX vs TAK, ZTS, HLN, TEVA, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SCYX Scynexis Inc	0.90	40.20M	20.60M	-8.61M	-5.28M	-0.1381
TAK Takeda Pharmaceutical Co Adr	18.04	56.99B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	115.93	48.94B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	9.70	43.30B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	29.14	33.94B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	531.82	23.31B	3.18B	1.33B	1.04B	27.90

Scynexis Inc Stock (SCYX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-22-21	Initiated	Guggenheim	Buy
Jan-06-21	Initiated	Cantor Fitzgerald	Overweight
Jul-11-18	Upgrade	Needham	Hold → Buy
Jun-27-18	Initiated	Maxim Group	Buy
Oct-24-17	Initiated	Guggenheim	Buy
Jul-10-17	Initiated	ROTH Capital	Buy
May-09-17	Downgrade	Needham	Buy → Hold
Mar-03-17	Reiterated	RBC Capital Mkts	Outperform
Oct-20-16	Initiated	H.C. Wainwright	Buy
Oct-07-16	Upgrade	WBB Securities	Buy → Strong Buy
Oct-03-16	Resumed	Brean Capital	Buy
Aug-17-16	Initiated	Guggenheim	Buy
Aug-09-16	Reiterated	Needham	Buy
Aug-09-16	Upgrade	WBB Securities	Speculative Buy → Buy
Mar-28-16	Initiated	Brean Capital	Buy
Dec-29-15	Initiated	WBB Securities	Speculative Buy
Nov-16-15	Reiterated	RBC Capital Mkts	Outperform
Jun-10-15	Initiated	Needham	Buy
May-29-14	Initiated	Canaccord Genuity	Buy
May-29-14	Initiated	RBC Capital Mkts	Outperform

View All

Scynexis Inc Stock (SCYX) Latest News

Mar 24, 2026

If You Invested $1,000 in Scynexis (SCYX) - Stock Titan

Mar 24, 2026

Mar 23, 2026

SCYNEXIS (NASDAQ:SCYX) Rating Lowered to “Hold” at Wall Street Zen - Defense World

Mar 23, 2026

Mar 22, 2026